[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, adenosine pathway & STING 2018

July 2018 | 204 pages | ID: CA5BBECBA80EN
La Merie Publishing

US$ 940.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, adenosine pathway & STING 2018

This Competitive Intelligence report analyzes the competitive field of modulators of the tumor microenvironment via IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING as of July 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage. The mainly selective, but also bispecific new molecular entities modulate the tumor microenvironment by targeting
  • IDO (Indoleamine 2,3-dioxygenase
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-?/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4)
  • Novel Chemokines (e.g. CCR2; CCR4, CXCL2, CXCR2, IL-8)
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47 – SIRP? (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase
At least 77 new molecular entities (NMEs) modulating the tumor microenvironment are in clinical development as monotherapy or in combination with checkpoint modulators or other active principles. At least 26 further NMEs are undergoing IND-enabling studies and numerous preclinical approaches are under evaluation.

The report includes a compilation of currently active projects in research and development of new molecular entities modulating the tumor microenvironment by targeting IDO & TDO, TGF-beta/R, CXCR4, novel chemokines, CSF-1R, CD47-SIRPalpha, adenosine pathway incl. CD73/CD39 and STING. In addition, the report lists company-specific R&D pipelines of modulators of the tumor microenvironment. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target/Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) TUMOR MICROENVIRONMENT MODULATION VIA IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, ADENOSINE PATHWAY & STING 2018

1a) IDO & TDO Inhibitors
  First-Generation Selective IDO-1 Inhibitors
  Novel Selective IDO-1 Inhibitors
  Dual IDO/TDO Inhibitors
  Selective TDO Inhibitors
  Other Approaches for IDO or TDO Inhibition
1b) TGF-beta Inhibitors
  Indirect TGF-beta Inhibition
  Selective TGF-beta1 Inhibitors
  Selective TGF-beta2 Inhibitors
  Dual or Triple TGF-beta Inhibitors
  Bispecific TGF-beta Inhibition
  1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors
  CXCR4 Antagonists
  CXCL12/SDF-1 Inhibitors
1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists
  Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
  Other Interleukin Inhibitors
  CCR2/CCR5 Antagonists
  CCR4 Antagonists
1e) CSF-1R Antagonists & CSF-1 Inhibitors
  Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
  Selective CSF-1R Antagonists and CSF-1 Inhibitors
1f) CD47 Antagonists & SIRPalpha Inhibitors
  CD47 Antagonists
  SIRP? Inhibitors
  Bispecific CD47 Antagonists
1g) Adenosine Pathway Modulation
  Selective Adenosine A2A Receptor Antagonists
  Selective Adenosine A2B Receptor Antagonists
  Dual Adenosine A2 Receptor Antagonists
  CD73 Ectoenzyme Inhibitors
  CD39 Ectoenzyme Inhibitors
  Other Approaches
1h) STING Agonists

2) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES


More Publications